Herbal hepatotoxicity: A critical review

British Journal of Clinical Pharmacology

Volumn 75, Issue 3, 2013, Pages 630-636

  Teschke, Rolf ^a   Frenzel, Christian ^b   Glass, Xaver ^c   Schulze, Johannes ^c   Eickhoff, Axel ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Causality assessment; Greater celandine hepatotoxicity; Herb induced liver injury; Herbal hepatotoxicity

Indexed keywords

HERBACEOUS AGENT;

ARTICLE; CHELIDONIUM; DRUG IMPURITY; DRUG LEGISLATION; LIVER INJURY; LIVER TOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG-INDUCED LIVER INJURY; HERBAL MEDICINE; HUMANS; LIVER; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL;

EID: 84873481116     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04395.x     Document Type: Article

References (74)

1. Carlsson C. Herbs and hepatitis. Lancet 1990; 336: 1068.
2. Huxtable RJ. The myth of beneficent nature: the risks of herbal preparations. Ann Intern Med 1992; 117: 165-166.
3. Colalto C. Unpredictable adverse reactions to herbal products. J Drug Metab Toxicol 2012; 3: 2. Available at http://www.omicsonline.org/2157-7609/2157-7609-3-e105.pdf (last accessed 4 July 2012
4. Teschke R, Glass X, Schulze J, Eickhoff A. Suspected Greater Celandine hepatotoxicity: liver specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol 2012; 24: 270-280.
5. Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011; 61: 282-291.
6. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArMBekanntmachung. Abwehr von Gefahren durch Arzneimittel, Stufe II, Anhörung: Schöllkraut-haltige Arzneimittel zur innerlichen Anwendung. 6 May 2005. Available at http://www.bfarm.de/cae/servlet/contentblob/1014620/publicationFile/66198/schoellkraut-anhoerung_050505.pdf (last accessed 4 July 2012
7. Colin-Johnes DG, Harvey J. Mistletoe hepatitis. BMJ 1982; 284: 744-745.
8. Beuers U, Spengler U, Pape GR. Hepatitis after chronic abuse of senna. Lancet 1991; 337: 372-373.
9. Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117: 129-132.
10. Perharic-Walton L, Murray V. Toxicity of traditional Chinese herbal remedies. Lancet 1992; 340: 674.
11. Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN, Michieletti P, Wanless IR, Stermitz FR, Beck JJ, Vierling JM. Acute hepatitis associated with the chinese herbal product Jin Bu Huan. Ann Intern Med 1994; 121: 729-735.
12. Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol 1995; 90: 831-833.
13. Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995; 36: 146-147.
14. Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hu-tangDig Dis Sci 1995; 40: 1845-1848.
15. Laliberté L, Villeneuve JP. Hepatitis after the use of Germander, a herbal remedy. Can Med Assoc J 1996; 154: 1689-1692.
16. Adachi M, Saito H, Kobayashi H, Horie Y, Kato S, Yoshioka M, Ishii H. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido. Ann Intern Med 2003; 139: 488-492.
17. Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138: 852-858.
18. Pak E, Esrason KT, Wu VH. Hepatotoxicity by herbal remedies: an emerging dilemma. Prog Transplant 2004; 14: 91-96.
19. Willett KL, Roth RA, Walker L. Workshop overview: hepatotoxicity assessment for botanical dietary supplements. Toxicol Sci 2004; 79: 4-9.
20. Bottenberg MM, Wall GC, Harvey RL, Habib S. Oral Aloe vera-induced hepatitis. Ann Pharmacother 2007; 41: 1740-1743.
21. Elinav E, Pinkser G, Safadi R, Pappo O, Bromberg M, Anis E, Keinan-Boker L, Broide E, Ackerman Z, Kaluski DN, Lev B, Shouval D. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J Hepatol 2007; 47: 514-520.
22. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, Oneta CM. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007; 47: 521-526.
23. Seeff KB. Herbal hepatotoxicity. Clin Liver Dis 2007; 11: 577-596.
24. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low Dog T. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf 2008; 31: 469-484.
25. Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 2009; 23: 366-373.
26. Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008; 14: 6999-7004.
27. Chan TYK. Potential risks associated with the use of herbal anti-obesity products. Drug Saf 2009; 32: 453-456.
28. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Exp. Opin Drug Metab Toxicol 2009; 5: 843-860.
29. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-341.
30. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 29: 373-382.
31. Licata A, Macaluso FS, Craxi A. Herbal hepatotoxicity: a hidden epidemic. Intern Emerg Med 2012 (in press
32. Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 2012 (in press
33. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
34. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
35. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-766.
36. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011; 11: 249-259.
37. Zimmerman HJ. Hepatotoxicity. Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
38. Teschke R, Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. Ann Hepatol 2009; 8: 258-266.
39. Teschke R. Black cohosh and suspected hepatotoxicity - inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: a critical review. Menopause 2010; 17: 426-440.
40. WHO. Guideline on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. Geneva: WHO, 2003; Available at http://whqlibdoc.who.int/publications/2003/9241546271.pdf (last accessed 4 July 2012
41. WHO. Technical Report Series, No. 937, 2006. Annex 3. Supplementary guidelines on good manufacturing practices for the manufacture of herbal medicines. Available at http://infocollections.org/medregpack/documents/d0099/d0099.pdf (last accessed 4 July 2012
42. WHO. Guidelines for assessing quality of herbal medicines with reference to contaminants and residues. 2007. Available at http://apps.who.int/medicinedocs/documents/s14878e/s14878e.pdf (last accessed 4 July 2012
43. Teschke R, Qiu SX, Lebot V. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liver Dis 2011; 43: 676-681.
44. Teschke R, Lebot V. Proposal for a kava quality standardization code. Food Chem Toxicol 2011; 49: 2503-2516.
45. Teschke R, Qiu SX, Xuan TD, Lebot V. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence. Phytother Res 2011; 25: 1262-1274.
46. Teschke R, Sarris J, Glass X, Schulze J. Kava, the anxiolytic herb: back to basics to prevent liver injury? Br J Clin Pharmacol 2011; 71: 445-448.
47. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network (DILINImportant elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-470.
48. Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions- a case study. Phytomedicine 2003; 10 (Suppl. IV): 68-73.
49. Teschke R, Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liver Dis 2009; 41: 891-901.
50. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann Hepatol 2009; 8: 184-195.
51. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, Nguyen H, Emerson SU, Purcell RH, Tillmann HL, Gu J, Serrano J, Hoofnagle JH, for the Drug-Induced Liver Injury Network (DILINAcute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141: 1665-1672.
52. Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions. Drug Saf 2010; 30: 765-773.
53. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-1193.
54. Teschke R. Kava hepatotoxicity - a clinical review. Ann Hepatol 2010; 9: 251-265.
55. Teschke R, Schmidt-Taenzer W, Wolff A. USP suspected herbal hepatotoxicity: quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmacoepidemiol Drug Saf 2012; 21: 336-338.
56. Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Reg Toxicol Pharmacol 2011; 59: 1-7.
57. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf 2011; 20: 567-582.
58. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
59. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-310.
60. WHO, World Health Organization. The use of the WHO-UMC system for standardised case causality assessment. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database 2000. Available at http://who-umc.org/Graphics/24734.pdf (last accessed 4 July 2012
61. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity - challenges and pitfalls of causality assessment. Maturitas 2009; 63: 302-314.
62. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolf A. Suspected black cohosh hepatotoxicity - causality assessment versus safety signal. Quality versus quantity. Maturitas 2009; 64: 141-142.
63. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003; 10: 440-446.
64. Stammschulte T, Gundert-Remy U. Letter to the Editor. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012 (in pressAvailable at http://dx.doi.org.10.101016/j.yrtph.2012.06.011 (last accessed 4 July 2012
65. Teschke R, Frenzel C, Schulze J, Eickhoff A. Suspected herbal hepatotoxicity: the pharmacovigilance dilemma with disputed and obsolete evaluation methods. Regul Toxicol Pharmacol 2012 (in pressAvailable at http://dx.doi.org/10.1016/j.yrtph.2012.06.010 (last accessed 4 July 2012
66. Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012; 63: 1-9.
67. Teschke R, Frenzel C, Wolff A, Herzog J, Glass X, Schulze J, Eickhoff A. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvements. Ann Hepatol 2012; 11: 500-512.
68. Davies EG, Pollock I, Steel HM. Chinese herbs for eczema. Lancet 1990; 336: 117.
69. Bae SH, Kim DH, Bae YS, Lee KJ, Kim DW, Yoon JB, Hong JH, Kim SH. Toxic hepatitis associated with Polygoni multiflori. Korean J Hepatol 2010; 16: 182-186.
70. Horowitz RS, Feldhaus K, Dart RC, Stermitz FR, Beck JJ. The clinical spectrum of Jin Bu Huang toxicity. Arch Intern Med 1996; 156: 899-903.
71. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal medication (extracts of kava or of common or lesser celandineDtsch Med Wochenschr 1998; 123: 1410-1414 (in German
72. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, Ma-huang. Am J Gastroentol 1996; 91: 1436-1438.
73. EMA: assessment of case reports connected to herbal medicinal products containing cimicifugae racemosae rhizoma (black cohosh, rootIssued 8 May 2007. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2010/02/WC500074167.pdf (last accessed 4 July 2012
74. Nebraska judgement of 8. September 2006. Available at http://ahpa.org/portals/0/pdfs/06_0908_Blackcohosh_NebraskaDistrictCt.pdf (last accessed 4 July 2012